Antifungal susceptibility testing: New technology and clinical applications

Infectious Disease Clinics of North America

Volumn 15, Issue 4, 2001, Pages 1227-1261

  Pfaller, M A ^a   Wen Liang Yu, ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PYRROLE DERIVATIVE; RAVUCONAZOLE; VORICONAZOLE;

AGAR GEL DIFFUSION; ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CANDIDA; COLORIMETRY; CRYPTOCOCCUS NEOFORMANS; DILUTION; FLOW CYTOMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; QUALITY CONTROL; REVIEW; SPECTROPHOTOMETRY; STANDARDIZATION; TECHNOLOGY;

EID: 0035217138     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70192-6     Document Type: Article

References (158)

1. The medical mycological iceberg
2. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
3. Disseminated trichosporonosis: Meeting the challenge
4. Fluconazole susceptibility testing of Candida albicans: Microtiter method that is independent of inoculum size, temperature, and time of reading
5. Quantitation of ergosterol content: Novel method for determination of fluconazole susceptibility of Candida albicans
6. Evaluation of growth characteristics on blood agar and eosin methylene blue agar for the identification of Candida (Torulopsis) glabrata
7. Fluconazole disk diffusion procedure for determining susceptibility of Candida species
8. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
9. Evaluation of the susceptibility of pathogenic Candida species to fluconazole
10. Molecular subtypes and anti fungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group
11. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I
12. Antifungal susceptibility testing using the E test: Comparison with the broth macrodilution technique
13. Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts
14. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
15. Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C. albicans and non-C. albicans spp: Results of a multicenter prospective study of candidemia
16. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing
17. Standardization of antifungal susceptibility testing
18. Comparison of a new commercial colorimetric microdilution method with a standard method for in vitro susceptibility testing of Candida spp. and Cryptococcus neoformans
19. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal susceptibility testing of Candida species and Cryptococcus neoformans
20. Itraconazole resistance in Aspergillus fumigatus
21. In vitro activities of BMS-207147 against over 600 contemporary clinical blood-stream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
22. Introduction to antifungal drugs
23. Nosocomial blood stream infections in United States hospitals: A three-year analysis
24. Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp.
25. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
26. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
27. Clinical relevance of antifungal resistance
28. In vitro activity of the new triazole voriconazole (UK-10,946) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
29. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY 303366 against filamentous and dimorphic fungi and yeasts
30. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests
31. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing of filamentous fungi
32. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans
33. An interlaboratory evaluation of the E test method for antifungal susceptibility testing of pathogenic yeasts for five antifungal agents using Casitone agar and solidified RPMI 1640 with 2% glucose
34. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
35. Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp, Cryptococcus spp, and other yeasts and yeast-like organisms
36. Antifungal agents and susceptibility tests
37. In vitro susceptibility pattern of Candida lusitaniae and evaluation of the E test method
38. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei
39. Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: Comparison with the broth macrodilution procedures
40. Epidemiology of nosocomial fungal infections
41. Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts
42. Susceptibility testing of fungi: Current status of the standardization process
43. Disseminated infection with Fusarium in recipients of bone marrow transplants
44. Susceptibility testing of Cryptococcus neoformans: A microdilution technique
45. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?
46. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect
47. Mycoses caused by Candida lusitaniae
48. Comparison of a 2, 3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium Hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents
49. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide assay
50. Fluconazole susceptibility testing of Cryptococcus neoformans: Comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients
51. In vitro activity of voriconazole, itraconazole, and amphotericin B against filamentous fungi
52. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infections
53. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
54. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice
55. Fluconazole disk diffusion susceptibility testing of Candida species
56. Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994
57. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
58. Evaluation of voriconazole pharmacodynamics using time-kill methodology
59. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
60. Amphotericin B resistance testing of Candida spp: A comparison of methods
61. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole
62. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods
63. Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination
64. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
65. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: Performance of three different media assessed by using E test and National Committee for Clinical Laboratory Standards M27-A methodologies
66. Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida and level of fluconazole susceptibility
67. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991
68. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi
69. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
70. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 294 clinical isolates of Candida spp.
71. Activity of MK-0991 (L-743,872) a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
72. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing bone marrow transplantation
73. The trailing end point phenotype in antifungal susceptibility testing is pH dependent
74. In vitro susceptibility tests: Correlations between sensitivity testing and clinical outcome in infected patients
75. In vitro evaluation of voriconazole against some clinically important fungi
76. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion
77. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method
78. The spectrum of non-Candida fungal infections following bone marrow transplantation
79. Antimicrobial susceptibility tests: Testing methods and interpretive problems
80. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
81. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models
82. Antifungal susceptibility testing of yeasts: Evaluation of technical variables for research automation
83. The epidemiology of invasive mycoses-narrowing the gap
84. Antifungal susceptibility testing: Progress and future developments
85. Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing
86. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine
87. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates
88. Multicenter evaluation of four methods of yeast inoculum preparation
89. Standardized susceptibility testing of fluconazole: An international collaborative study
90. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans
91. Blood stream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998
92. International surveillance of blood stream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America of the SENTRY Program
93. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
94. International surveillance of blood stream infections due to Candida species: Frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole, and voriconazole among isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program
95. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
96. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
97. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans blood stream isolates
98. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rizopus, and other filamentous fungi
99. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Sacharomyces cerevisiae
100. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870
101. Evaluation of the E test method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media
102. Evaluation of E test for determining in vitro susceptibility of yeast isolates to amphotericin B
103. Evaluation of the E test method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media
104. In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
105. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
106. In vitro susceptibility testing of filamentous fungi: Comparison of E test and reference microdilution methods for determining itraconazole MICs
107. Multisite reproducibility of the E test MIC method for antifungal susceptibility testing of yeast isolates
108. National epidemiology of mycoses survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species
109. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
110. Antifungal susceptibility testing: Technical advances and potential clinical applications
111. Collaborative investigation of variables in susceptibility testing of yeasts
112. Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates
113. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
114. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
115. National epidemiology of mycoses survey (NEMIS): Variations in rates of blood stream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units
116. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test
117. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis
118. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of a population-based laboratory active surveillance
119. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance
120. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
121. Detection of amphotericin B-resistant Candida isolates in a broth-based system
122. Susceptibility testing of current Candida blood stream isolates from Mycoses Study Group (MSG) collaborative study #34: Isolates of C. krusei are often resistant to both fluconazole and amphotericin B
123. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
124. Antifungal susceptibility testing
125. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro - In vivo correlation data for fluconazole, itraconazole, and Candida infections
126. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of ketoconazole and itraconazole
127. Resistance of Candida species to fluconazole
128. Practice guidelines for the treatment of candidiasis
129. Determination of antifungal MICs by a rapid susceptibility assay
130. Defining conditions for microbroth antifungal susceptibility tests: Influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria
131. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans
132. Risk factors for candidemia in neonatal intensive care unit patients
133. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole
134. E test, an antimicrobial susceptibility testing method with broad clinical and epidemiologic application
135. Do in vitro antimicrobial susceptibility tests accurately predict therapeutic responsiveness in infected patients?
136. New aspects of emerging fungal pathogens: A multifaceted challenge
137. Antifungal susceptibility testing of yeasts: A brief overview
138. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test
139. Practice guidelines for the treatment of fungal infections
140. In vitro testing: Correlations between bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy
141. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
142. Comparison of E test and broth microdilution methods for antifungal drug susceptibility testing of molds
143. Use of a colorimetric system for yeast susceptibility testing
144. Comparative evaluation of macrodilution and Alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates
145. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E test and semiautomated broth microdilution test
146. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
147. Candida, Cryptococcus, and other yeasts of medical importance
148. Rapid susceptibility testing of fungi by flow cytometry using vital staining
149. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
150. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing
151. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
152. High-frequency in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance